Understanding stroke and heart disease in women remains a major research priority
Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year s Go Red for Women® special issue of the American Heart Association s flagship journal
Circulation, published online today.
Circulation editors said more than 100 manuscripts were submitted this year, the most ever in the five years in which the current editorial board has published the special issue.
Undeniably, cardiovascular disease remains the number one killer of women around the world, taking the lives of 1 in 3 women. Even one life lost is too many, because we know much of heart disease and stroke is preventable and treatable.Support for ongoing research, as well as female participation in pivotal clinical trials, are imperative to effectively address sex disparities in heart disease and stroke care as part of
Knowing Heart Disease, Stroke in Women Remains Research Priority medindia.net - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medindia.net Daily Mail and Mail on Sunday newspapers.
E-Mail
DALLAS, Feb. 15, 2021 Understanding the sex differences in cardiovascular disease presentation and outcomes remains a major research priority demonstrated by the record number of submissions for this year s Go Red for Women® special issue of the American Heart Association s flagship journal
Circulation, published online today.
Circulation editors said more than 100 manuscripts were submitted this year, the most ever in the five years in which the current editorial board has published the special issue. Undeniably, cardiovascular disease remains the number one killer of women around the world, taking the lives of 1 in 3 women. Even one life lost is too many, because we know much of heart disease and stroke is preventable and treatable, said
Press release content from PR Newswire. The AP news staff was not involved in its creation.
VOLTA MEDICAL raises 28 million USD to revolutionize persistent AFib ablation
January 5, 2021 GMT
Volta Medical logo
MARSEILLE, France, Jan. 5, 2021 /PRNewswire/ Volta Medical, a pioneering French-based HealthTech startup, working on novel artificial intelligence (AI) algorithms to treat cardiac arrythmias, today announced that it has successfully raised 28 million USD. The financing round was led by Gilde Healthcare with participation of existing shareholder Pasteur Mutualité. The new capital will allow the company to establish its revolutionary FDA-cleared and CE marked VX1 AI software solution as a new standard of care, pursue further R&D activities and start to roll out commercial activities across the US and Europe. Recruitment for TAILORED-AF, an international multicenter trial has already started. Volta Medical will be welcoming two new Board members. Janke Dittmer, General Partn